Log In
BCIQ
Print this Print this
 

JZP-110 (formerly ADX-N05)

Also known as: formerly ARL-N05, SKL-N05

  Manage Alerts
Collapse Summary General Information
Company SK Biopharmaceuticals Co. Ltd.
DescriptionPhenylalanine derivative
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationExcessive sleepiness
Indication DetailsTreat excessive daytime sleepiness in patients with narcolepsy; Treat excessive daytime sleepiness in patients with obstructive sleep apnea
Regulatory Designation
PartnerJazz Pharmaceuticals plc

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$397.0M

$125.0M

$272.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

01/20/2014

$397.0M

$125.0M

$272.0M

Get a free BioCentury trial today